Neuroendocrine tumors have demonstrated an increase in incidence ... option for patients with high tumor content of somatostatin type 2 receptors and will be further developed in the future.
Some people use Zollinger-Ellison syndrome and gastrinoma interchangeably. Learn the similarities and differences between the ...
Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.
sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...
After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback